SCHEMBL22279461

SCHEMBL22279461

CC(I)C(=O)Oc1ccc(C(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.56
▸ ELANE P08246 3/20 0.55
▸ HSD17B10 Q99714 1/20 0.53
▸ CA1 P00915 1/20 0.52
▸ CA2 P00918 1/20 0.52
▸ MAPK1 P28482 1/20 0.49
▸ MAPT P10636 1/20 0.47
▸ TP53 P04637 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ RXRA P19793 2/20 0.44
▸ RXRB P28702 2/20 0.44
▸ SRD5A2 P31213 2/20 0.43
▸ PARP15 Q460N3 1/20 0.43
▸ PARP10 Q53GL7 1/20 0.43
▸ RARB P10826 1/20 0.43
▸ TPMT P51580 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12617490 0.85 ELANE (0.75) KMT2AELANEHSD17B10CA1CA2
SCHEMBL21276510 0.82 ELANE (0.53) KMT2AELANEHSD17B10MAPTTP53
SCHEMBL22279621 0.81 PLA2G2A (0.41) KMT2AELANECA1CA2MAPT
SCHEMBL12693511 0.81 KMT2A (0.56) KMT2AELANEHSD17B10CA1CA2
SCHEMBL7184479 0.81 KMT2A (0.56) KMT2AELANEHSD17B10CA1CA2
SCHEMBL11991232 0.81 KMT2A (0.56) KMT2AELANEHSD17B10CA1CA2
SCHEMBL364405 0.81 KMT2A (0.56) KMT2AELANEHSD17B10CA1CA2
SCHEMBL18844947 0.81 MAPT (0.51) KMT2AELANEHSD17B10CA1CA2
SCHEMBL9337509 0.80 CA1 (0.55) KMT2AELANEHSD17B10CA1CA2
SCHEMBL9337519 0.80 CA1 (0.55) KMT2AELANEHSD17B10CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240027902-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-01-25 — — US disclosed
US-20240027902-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-01-25 — — US disclosed
US-11720020-B2 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-08-08 — — US disclosed
US-11586110-B2 Positive resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-02-21 — — US disclosed
US-11415887-B2 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2022-08-16 — — US disclosed
US-20210033969-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-02-04 — — US disclosed
US-20210033970-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-02-04 — — US disclosed
US-20210033971-A1 POSITIVE RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-02-04 — — US disclosed
US-20200272048-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2020-08-27 — — US disclosed
US-20200241414-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2020-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200241414-A1 RESIST COMPOSITION AND PATTERNING PROCESS INSR, HNRNPU, HNRNPR KMT2A 1882/4885ELANE 2178/4885HSD17B10 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback